



FOR IMMEDIATE RELEASE

September 16, 2013

Contact:

Matthew McClorey

Chief Operating Officer

785-841-7120

mmcclorey@crititech.com

Critech Expands Into New Headquarters

LAWRENCE, KS – Critech, a rapidly growing drug development company, announced today that it has completed its move into a new 10,000 square-foot headquarters in North Lawrence.

The new headquarters – located at 1849 E. 1450 Road – will house all of the company's operations under one roof, including administration, management, research and development, drug development services, its analytical laboratories and future API manufacturing.

"We are very excited about our new home," said Matthew McClorey, Critech's Chief Operating Officer. "Due to the growth the company has experienced over the past year, we needed more space to accommodate our growing laboratory and forthcoming API manufacturing operations."

Critech's focus at its new facility will be using its proprietary fine-particle drug development and production technology to help its customers develop new, improved and differentiated human and animal pharmaceutical drugs. Critech expects to use the manufacturing space in its facility to produce API for clients as they advance their drugs from the research and development stage through Phase I and Phase II clinical trials.

"Our target is to be operating in a FDA-regulated, cGMP compliant environment later this year," said Gary Clapp, Vice President of Technical Operations. "The new facility has been very helpful in showcasing our resources and expertise in fine particle drug

development. The new laboratories, analytical equipment and manufacturing capabilities have impressed potential clients, customers and strategic partners. They can now see CritiTech has completed the transition from an R&D company to one that is ready to work hands on with them to develop and produce fine particle drugs that have a competitive advantage and distinct value proposition.”

Earlier this year, enrollment for CritiTech’s Phase I Trial for Nanotax[®], a fine particle reformulation of paclitaxel to treat intraperitoneal cancers, was completed at the University of Kansas Cancer Center. The trial is expected to be reported this fall and a Phase II clinical study will commence in mid-2014.

About CritiTech

CritiTech, Inc. is a drug development company focused on applying the company’s proprietary Super Critical Fluid (SCF) Technology to help its clients and partners develop and manufacture unique and differentiated drugs and medical devices for the human and animal health markets. CritiTech specializes in optimizing the delivery of challenging drug substances – potent molecules, poorly soluble compounds and biomolecules. By combining its SCF Technology with its ability to simplify formulations, CritiTech can expand and improve the drug delivery options for oral, injectable, and inhaled drugs, as well as implantable devices.

For more information about CritiTech, please visit www.crititech.com.